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Genetic Variants and Risk of Chronic Kidney Disease  
Genetic factors are increasingly recognized to contribute to the risk of chronic kidney disease, 
and important differences in the risk of progression to end-stage renal disease have been 
observed in different racial groups (1). In particular, African American patients have 4- to 5-
fold more kidney failure than white patients. Identifying genetic factors contributing to this 
increased risk is of major importance to address renal disease progression (2). 
Seminal investigations led by Martin Pollak and colleagues have shown that a locus on 
chromosome 22 (22q.13) accounts for the essential of the increased risk of end-stage renal 
disease in black patients. The risk is associated with two variants in the APOL1 gene that 
encodes apolipoprotein L1 (ApoL1), which is part of a circulating protein complex that can 
lyse Trypanosoma brucei and other trypanosomes responsible for the African sleeping 
sickness. While humans are resistant to T. brucei because of ApoL1, a virulent subspecies (T. 
brucei rhodesiense) has emerged, that is resistant to ApoL1-mediated lysis. The two variants 
of APOL1, called G1 and G2, confer protection against potentially lethal infections by T. 
brucei rhodesiense, explaining why they are frequent in populations of recent African descent 
(2). In fact, about 50% of African Americans having either one or two APOL1 G1 or G2 risk 
alleles. 
Recently, Parsa et al. have extended the APOL1 paradigm, by examining the effect of 
the G1 and G2 variants of APOL1 on the progression of chronic kidney disease in two 
prospective, multicenter studies involving patients with chronic kidney disease: the African 
American Study of Kidney Disease and Hypertension (AASK, 693 patients) and the Chronic 
Renal Insufficiency Cohort (CRIC, 2955 patients) (3). The high-risk group was defined as 
having 2 copies of high risk variants, whereas the low-risk group had 0 or 1 copy. A 
consistent and robust association between the presence of APOL1 risk variants and higher 
rates of end-stage renal disease and progression of chronic kidney disease was observed in 
black patients as compared with white patients, regardless of diabetes status. In the AASK 
study for instance, patients with 2 copies of APOL1 risk variants were twice as likely to 
progress to the composite of end-satge renal disease or a reduction of 50% in the eGFR from 
baseline over a median follow-up of 9 years. Of note, the progression of CKD was not 
influenced by blood pressure control (as compared to the APOL1 status), and there was no 
interaction between the APOL1 genotype and treatment with an ACE inhibitor in the black 
population. 
These studies confirm the robust association of renal risk variants in APOL1 with 
higher rates of end-stage renal disease and progression of chronic non-diabetic kidney disease 
in black patients as compared with white patients. They also demonstrate that, in a context of 
recent selection pressure against pathogens in African Americans, a risk variant that is 
relatively frequent may also have a large effect size (2). Future research will need to address 
the mechanism by which ApoL1 cause renal disease (we only known that ApoL1 is expressed 
in the glomerulus), as well as the inconsistent effect of APOL1 genotype in patients with 
diabetic kidney disease. 
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